Hot Features
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in... X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.18 | -4.2654028436 | 4.22 | 4.425 | 3.92 | 527562 | 4.05118422 | CS |
| 4 | -0.08 | -1.94174757282 | 4.12 | 4.425 | 3.66 | 502937 | 4.02881176 | CS |
| 12 | -0.2 | -4.71698113208 | 4.24 | 4.66 | 3.56 | 412972 | 4.08943256 | CS |
| 26 | -0.39 | -8.80361173815 | 4.43 | 4.83 | 2.83 | 444445 | 3.92857081 | CS |
| 52 | 1.96 | 94.2307692308 | 2.08 | 4.83 | 1.35 | 1515706 | 3.01663388 | CS |
| 156 | 2.09 | 107.179487179 | 1.95 | 6.63 | 0.1701 | 2052891 | 1.38846956 | CS |
| 260 | -3.03 | -42.8571428571 | 7.07 | 7.13 | 0.1701 | 1638920 | 1.48046038 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.